Uncategorized
FDA, Moderna appear aligned on mRNA flu shot heading into adcomm
Uncategorized
Moderna’s FDA adcomm, IPO mania, biopharma layoffs, more
Moderna appears to have aligned with the FDA ahead of an advisory committee meeting for its mRNA-based flu vaccine, which the regulator initially turned away in February; biotech IPOs are going gangbusters, including two new records raises in as many weeks; layoffs continue across biopharma; plus much more.
Uncategorized
PwC declares biopharma ecosystem ‘back to full health’ as M&A buoys sector
Precision science is ruling the M&A scene as pharmas prepare for loss of exclusivity on key products, PwC says in a new report. Biotechs should be prepared with a dual-track process with the IPO window now open.
Uncategorized
A new Westlake-backed biotech takes aim at migraines
Vedana Therapeutics emerged from stealth Wednesday with $46 million to support its mission of developing “anti-PACAP” therapies, an increasingly popular strategy for migraine prevention.
Vedana Therapeutics emerged from stealth Wednesday with $46 million to support its mission of developing “anti-PACAP” therapies, an increasingly popular strategy for migraine prevention.
-
Uncategorized9 years agoThese ’90s fashion trends are making a comeback in 2017
-
Uncategorized9 years agoAccording to Dior Couture, this taboo fashion accessory is back
-
Endpoints News3 months ago
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
-
Uncategorized9 years agoPhillies’ Aaron Altherr makes mind-boggling barehanded play
-
Uncategorized9 years agoUber and Lyft are finally available in all of New York State
-
Uncategorized9 years agoSteph Curry finally got the contract he deserves from the Warriors
-
Contributors9 years agoThe final 6 ‘Game of Thrones’ episodes might feel like a full season
-
Uncategorized3 months agoNovartis buys Synnovation’s PI3Kα inhibitors for $3 billion